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Abstract
Introduction. Familial hypercholesterolemia (FH) is an autosomal dominant inherited 
disease characterized by elevated plasma low-density lipoprotein cholesterol (LDL-C). 
Targeted Next Generation Sequencing (NGS) is a new opportunity to expand the ex-
isting pathogenic variants (PVs) spectrum associated to FH. Our aim was to report a 
diagnostic NGS-based approach to detect variants associated to FH. 
Methods. We report two patients: a 48-year-old Asian woman, without known history 
of hypercholesterolemia and a 46-year-old Caucasian man, with childhood hypercholes-
terolemia. 
Results. An effective NGS-based pipeline, FH-Devyser kit/Amplicon Suite, beginning 
from sequencing to data analysis, did not identify known PVs in the LDLR, APOB, 
APOE, LDLRAP1, STAP1 and PCSK9 genes, but revealed two novel LDLR variants 
(c.1564A>T, p.Ile522Phe and c.1688C>T, p.Pro563Leu). 
Discussion and conclusions. This study showed that an effective NGS-based pipeline 
led to a definitive diagnosis in two FH families, allowing to plan their therapeutic treat-
ment. Although the functional consequence of the two LDLR variants needs to be as-
sessed in vitro, the in silico analysis and high preservation of the two amino acid positions 
observed in the LDLR protein, across different animal species, suggest that both variants 
are deleterious.
INTRODUCTION
Three canonical genes underlie autosomal dominant 
familial hypercholesterolemia (ADFH): low-density 
lipoprotein receptor (LDLR) (FH-type 1), apolipo-
protein B (APOB) (FH-type 2) and pro-protein con-
vertase subtilisin/kexin 9 (PCSK9) (FH-type 3). Other 
genes, like signal transducing adaptor family member 
1 (STAP1) (FH-type 4) and apolipoprotein E (APOE) 
(FH-type 5) have been associated to some rare FH 
forms [1]. In addition, FH-like phenotypes, with a re-
cessive transmission, are extremely rare. This group of 
disorders includes the classic autosomal recessive hy-
percholesterolemia (ARH) caused by mutations in the 
Low Density Lipoprotein Receptor Adaptor Protein 1 
(LDLRAP1) gene [2].
Successful molecular diagnosis depends on the ability 
of the designated method to identify molecular lesion 
associated with FH [3]. Next Generation Sequencing 
(NGS) allows molecular diagnostic laboratories to in-
crease sample throughput, to reduce the turn-around 
time and to analyse more disease-related genes simul-
taneously. As a result, recent studies demonstrated that 
NGS-based assays are very useful and at the same time 
cost effective for the genetic diagnosis of FH in primary 
care [4]. However, the main challenge to translate NGS 
in clinical practice is to develop a simple and robust 
diagnostics and bioinformatics pipeline, fulfilling the 
quality control requirements for clinical diagnosis. 
We present an effective NGS-based pipeline, from 
sequencing to data analysis, which identified two unre-
ported LDLR variants in two FH families. 
CASES’ PRESENTATION
Case A
Index case A is a 48-year-old Asian woman, without 
known history of hypercholesterolemia. During a rou-
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tine blood examination, high LDL-C levels (324 mg/dl) 
were revealed (Table 1). Deeper insights on her family 
history disclosed two already deceased brothers from 
heart attack at the age of 48 and 54, respectively. Her 
parents’ medical history remained unclear. No tendon 
xanthoma or corneal arcus were diagnosed during physi-
cal examination. The patient had no other cardio-vas-
cular (CV) risk factors as smoking, diabetes and CHD 
history. Her body mass index was 21 kg/m2and she was 
normotensive.
The patient’s Dutch Lipid Clinic Network diagnostic 
criteria for FH score was 10, indicating a definite FH 
diagnosis. Therefore, we performed genetic evaluation, 
according with EAS/ESC guidelines [5]. Furthermore, 
her 13-year-old son and 14-year-old daughter, whose 
lipid profile (Table 1) was clearly indicative of FH, un-
derwent genetic testing.
Case B
Index case B is a 46-year-old Caucasian man, suffer-
ing from hypercholesterolemia since his childhood, in 
absence of CV history. The patient complained about 
muscle pain and cramps due to statin therapy, which 
was, therefore, suspended for about a month. His blood 
examination showed high LDL-C levels (313 mg/dl), 
despite ongoing therapy with ezetimibe and fibrate (Ta-
ble 1). Family history revealed that his mother suffered 
from severe hypercholesterolemia, even if no familial 
CV events were reported. No tendon xanthoma or cor-
neal arcus were diagnosed during physical examination. 
He did not show additional CV risk factors, such as 
smoking and diabetes, while he presented with a nor-
mal BMI of 22 kg/m2 and normotensive status.
Considering that his Dutch Score was 9, which is re-
lated to a definite diagnosis of FH, according with EAS/
ESC guidelines, the genetic evaluation was performed.
The two patients gave their written informed consent 
prior to blood sampling. Genomic DNA was isolated 
from peripheral blood by an automatic device (Mag-
Core HF16 Plus, Diatech Lab Line, Jesi, Italy). We 
used 30 ng input DNA for the analysis with the NGS-
based method (Devyser FH kit, Devyser, Hägersten, 
Sweden). All exons, the exon–intron boundaries, 5' and 
3' untranslated regions of six FH-related genes (LDLR, 
APOB, PCSK9, LDLRAP1, APOE and STAP1) and 
polymorphisms, associated with polygenic FH form and 
statin treatment effects, were examined [6]. The design 
was based on the human (Hg19) reference genome to 
generate 200-bp amplicons by using 192 primer pairs 
designed and mixed in a single tube. The Qubit® 2.0 
Fluorometer 8 (Life Technologies) was used to normal-
ize the genomic DNA concentrations to 2 ng/μl. The 
final libraries were quantified on Qubit®, diluted to a 
concentration of approximately 7 pM and denatured to 
ensure the efficient use of the MiSeq Reagent Kit (Il-
lumina, CA, USA).
MATERIALS AND METHODS
NGS pipeline and Sanger sequencing
Each NGS run consisted of eight FH samples 
loaded on MiSeq Reagent Kit v2 Nano cartridge, us-
ing 2 × 150-bp paired-end chemistry, according to 
manufacturer instructions. MiSeq-generated FASTQ 
files were downloaded and processed using Amplicon 
Suite software (SmartSeq s.r.l, Novara, Italy) provid-
ing integrated tools for the analysis, visualization and 
interpretation of NGS data. Proprietary algorithms 
based on coverage depth and uniformity were applied 
for copy number variation (CNV) detection in the 
LDLR gene. Sanger sequencing was performed with 
an Applied Biosystems 3500 Genetic Analyzer (Life 
Technologies, Carlsbad, CA, USA). Sequence analy-
sis was carried out with the SeqScape Software v2.5. 
The primers were designed by Primers 3 software 
(http://primer3.ut.ee/). Their sequences were: forward 
(F) 5’-ACTGGATCCACAGCAACATCT-3’ and re-
verse (R) 5’-TGGGATTACAGGTGCTTTGAG-3’ and 
(F) 5’-AGCTATTCTCTGTCCTCCCA-3’ and (R) 
5’-CTTCAGGGAGCAGCTTGG-3’, able to amplify 
and sequence the LDLR exons 10 and 11, respectively. 
Prediction of variant effects and species sequence 
alignment
Four different programs were used to predict patho-
genicity of the two LDLR variants identified in this 
study: Polymorphism Phenotyping version 2 (http://ge-
netics.bwh.harvard.edu/pph2/), Sorting Intolerant From 
Tolerant (http://sift.jcvi.org/www/SIFT_enst_submit.
html), Mutation Taster (http://www.mutationtaster.org) 
and Provean (http://provean.jcvi.org/index.php). In ad-
dition, multiple sequence alignment was created using 
Clustal Omega (http://www.ebi.ac.uk/Tools/msa/clust-
alo/). The reference sequence used for LDLR protein 
was P01130.1 (SwissProt). 
Table 1
Lipid profile of the two index cases and their family’s members. The values beyond the normal reference ranges are highlighted 
in bold
Lipid fraction Case A Case B Laboratory reference ranges*
(mg/dl)
Proband Son Doughter Proband -
Total cholesterol 406 319 302 402 < 200
HDL-C 66 50 51 73 > 45
Triglycerides  78 62 72 82 20-170
LDL-C 324 258 237 313 < 130
Apo-B 145 169 167 85 55-130
*target therapy ranges were instead defined according to ESC/EAS guidelines [5]
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RESULTS
FH testing obtained by NGS did not reveal any 
known PVs in all genes investigated and no bioinfor-
matics algorithms were suggestive for the presence of 
CNV in the LDLR gene. However, we found two LDLR 
variants (c.1564A > T, coverage: 325/643X, allele fre-
quency: 50%, p.Ile522Phe) and c.1688C > T, coverage: 
219/433X, allele frequency: 50%, p.Pro563Leu) in case 
A and B, respectively (Figure 1). The nomenclature of 
the variants is based on the LDLR sequence (NCBI 
Reference Sequence: NM_000527.4; GRCh37), ac-
cording to the recommendations of the Human Ge-
nome Variation Society (https://www.hgvs.org) (Table 
2). Sanger sequencing confirmed the presence of both 
variants on a second independent patient sample. 
These variants were considered as novel since they were 
neither found in ClinVar (https://www.ncbi.nlm.nih.gov/
clinvar/), Ensemble Human Genome Mutation (https://
www.ensembl.org/index.html), ExAC (http://exac.
broadinstitute.org) nor 1000G (http://www.internation-
algenome.org/1000-genomes-browsers/) browsers. In 
addition, among more than 200 alleles routinely analysed 
by NGS-based molecular screening, we did not identify 
the two variants in other FH or healthy individuals. 
Other family members were not testable for the 
variant p.(Pro563Leu). Instead, we conducted family 
screening on two hypercholesterolemic subjects (the 
patient’s sons) for the variant p.(Ile522Phe). Both sub-
jects resulted to be carriers of the variant, providing evi-
dence for his co-segregation genotype/phenotype.
In silico analysis of the p.(Ile522Phe) and 
p.(Pro563Leu) variants, performed with four different 
prediction tools, suggested that both LDLR variants are 
deleterious (Table 1). In addition, the alignment of the 
amino acids in the LDLR protein across seven differ-
ent animal species, ranging from Homo sapiens to Ovis 
aries (sheep), showed that two amino acids (in humans: 
Ile522, and Pro563) are highly preserved (Figure 2). 
DISCUSSION
FH diagnosis is usually based on clinical features, 
such as physical findings of tendon xanthomas or corne-
Figure 1 
 
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure 1. BAM files visualized by the Integrative Genomics Viewer show the reads associated to 
c.1564A>T, p.(Ile522Phe) (A) and c.1688C>T, p.(Pro563Leu) (B) with a coverage of 325/643X 
(variant allele frequency: 50%) and 219/433X (variant allele frequency: 50%), respectively. The 
arrows indicate the nucleotide position of the two LDLR variants. 
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al arcus, cardio-vascular heart disease history, and high 
LDL-C concentrations. About 50% of heterozygous 
FH patients lack obvious phenotypes. Thus, many pa-
tients are underdiagnosed until they suffer from acute 
cardio-vascular events [7]. Previous studies indicated 
that in many countries less than 1% of FH individuals 
were correctly diagnosed with FH [8], partly due to the 
lack of reliable cost-effective genetic testing.
Genetic testing can provide a definitive diagnosis. 
Possible benefits include individual patient manage-
ment. For instance, heterozygous FH from CNVs 
seems to be a more severe phenotype than FH com-
pared to single nucleotide variants. Genetic diagnosis 
could reduce delays for appropriate treatment, possi-
bly more aggressive LDL-C lowering strategies [9, 10]. 
Additionally, for some monogenic dyslipidaemias, a 
genetic diagnosis is needed to ensure funding for new-
er therapies. This is the case of inhibitors of PCSK9, 
where, in certain jurisdictions, third party private cov-
erage for the treatment of FH requires a genetic diag-
nosis [11, 12].
In different FH patient cohorts, PVs in LDLR gene 
are found in more than 85-90% of FH cases and more 
than 1800 PVs of this gene have been reported and an-
notated in the UCL database (http://www.ucl.ac.uk/
ldlr/LOVDv.1.1.0/)
The heterogeneity of FH-causing variants supports 
the sequencing-based techniques as the primary meth-
odology to detect the disease and recent advances im-
proved accessibility for diagnostic use. This is the case 
of the targeted NGS in which only genes specifically 
involved in FH pathogenesis are screened.
In the present study, targeted sequencing of six genes 
(LDLR, APOB, PCSK9, APOE, LDLRAP1 and STAP1) 
performed by an effective NGS-based molecular pipe-
line (FH-Devyser Kit/Amplicon Suite software) allowed to 
identify two novel LDLR variants. 
The first, namely c.1564A>T, causes substitution of 
isoleucine for phenylalanine residue (p.Ile522Phe) in 
the LDL-receptor class B3 domain (486-528aa). The 
second, c.1688C>T, causes substitution of proline for 
leucine residue (p.Pro563Leu) in the LDL-receptor 
class B4 domain (529-572 aa). Both variants are locat-
ed in the very conservative ß-propeller domain, in the 
YWTD 3 and 4 repeats of the LDLR receptor, respec-
tively [13]. Both protein positions result to be extremely 
conserved in the species in which they were analysed. 
For this reason, in silico predictions performed with four 
different tools, using mainly amino acid conservation 
analysis, suggested that both LDLR variants are del-
eterious. Furthermore, at least in the family with the 
p.(Ile522Phe) variant, this FH-related mutation segre-
gates with high serum LDL-C levels, linking the variant 
with the phenotype.
In addition, the p.(Pro563Leu) variant occurs at the 
same position as other pathogenic missense changes: 
the c.1688C>A, rs879254987, (p.Pro563His) and the 
c.1687C>T, rs879254986, p.(Pro563Ser). Regarding 
the c.1564A>T variant, we underline that it is in the 
proximity of three missense substitutions: c.1567G>A, 
rs28942080, p.(Val523Met), c.1567G>T, rs28942080, 
p.(Val523Leu) and c.1561G>A, rs879254940, 
p.(Ala521Thr), showing discordant pathogenicity 
data. We underline that these findings provide further 
evidence in order to consider p.(Pro563Leu) and 
(p.Ile522Phe) as deleterious variants.
CONCLUSIONS
In this study, targeted sequencing of six genes (LDLR, 
APOB, PCSK9, APOE, LDLRAP1 and STAP1) per-
formed by an effective NGS-based molecular approach 
(FH-Devyser Kit/Amplicon Suite software) allowed to iden-
tify two novel LDLR variants in FH families. Although 
the functional consequence of the p.(Ile522Phe) and 
the p.(Pro563Leu) variants remains to be determined 
in vitro, we believe these substitutions should be consid-
ered as “likely pathogenic variants”.
Finally, we underline that NGS integration with other 
molecular and cellular techniques, to assess the signifi-
cance of VUS or novel variants, will improve the sen-
sitivity of FH testing entirely, supporting personalized 
medicine. 
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Table 2
Identities of the two LDLR variants and in silico prediction of their effect at protein level. Both variants show high scores of patho-
genicity for all four software used; following the ACMG guidelines, the c.1564A>T and the c.1688C>T can be classified as likely 
pathogenic variants
Transcript Coding 
impact
HGVS 
coding
HGVS 
protein 
level
Location Protein 
position
Splice 
distance
PolyPhen-2
(range:  
0-1)
SIFT
(cutoff = 
0.05)
Mutation 
Taster
Provean
(cutoff =  
-2.5)
ACMG 
classification*
NM_000527.4 M c.1564A>T I522F 
p.(Ile522Phe)
exon 10 
of 18 
206 of 
228 
(coding)
-23 Probably 
damaging
(score = 
0.990)
Damaging
(score = 
0.001)
Disease 
causing
Deleterious
(score = 
 -3.92)
Likely 
pathogenic
(PM1+PM2+ 
PP1+PP3)
M c.1688C>T P563L
p.(Pro563Leu)
exon 11 
of 18
102 of 
119 
(coding)
-18 Probably 
damaging
(score = 1)
Damaging
(score = 0)
Disease 
causing
Deleterious
(score = 
  -9.39)
Likely 
pathogenic
(PM1+PM2+ 
PM5+PP3)
*Interpretation of variants pathogenicity based on the American the College of Medical Genetics and Genomics (ACMG) recommendations [15], i.e., PM1: located in a 
mutational hot spot and/or in critical functional domain, PM2: absent from controls, PM5: novel missense change at amino acid residue where a different pathogenic 
missense change has been seen before, PP1: co-segregation with disease in multiple affected family members, PP3: multiple lines of computational evidence support 
a deleterious effect on the gene or gene product.
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(SP|P01130|LDLR_HUMAN: Ile522, and Pro563) show a high conservation between the species. 
This evidence underlines that both amino acid positions are preserved. 
	
Figure 2
The alignment of the LDLR aminoacids in seven different species and a consensus of 89 YWTD domains (CONS_Y3 and Y4) are shown. The 
residues predicted to be in b-strand [13,14] are highlighted in grey. The amino acids (SP|P01130|LDLR_HUMAN: Ile522, and Pro563) show high 
conservation between the species analysed.
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